Notes to Consolidated Financial Statements — (Continued) Becton, Dickinson and Company Table of Contents Financial information for the Company’s segments is detailed below. The Company has no material intersegment revenues. As discussed in Note 10, the Company completed its acquisition of Bard on December 29, 2017. Bard's operating results were included in the Company’s consolidated results of operations beginning on January 1, 2018. (a) The amounts in fiscal years 2019 and 2018 reflect the reclassification of U.S. revenues of $11 million and $17 million, respectively, associated with the movement, effective on October 1, 2019, of certain products from the Medication Delivery Solutions unit to the Medication Management Solutions unit. (b) The amounts in fiscal years 2019 and 2018 reflect the total reclassifications of $130 million and $134 million, respectively, of U.S. revenues and $55 million and $60 million, respectively, of international revenues associated with the movement, effective on October 1, 2019, of certain products from the Surgery unit and the Urology and Critical Care unit to the Peripheral Intervention unit. 72 (Millions of dollars) 2020 2019 2018 United States International Total United States International Total United States International Total Medical Medication Delivery Solutions (a) $ 1,972  $ 1,583  $ 3,555  $ 2,037  $ 1,811  $ 3,848  $ 1,875  $ 1,752  $ 3,627  Medication Management Solutions (a) 1,865  589  2,454  2,115  525  2,640  1,974  513  2,487  Diabetes Care 562  522  1,084  573  538  1,110  564  541  1,105  Pharmaceutical Systems 404  1,184  1,588  392  1,073  1,465  357  1,040  1,397  Total segment revenues $ 4,802  $ 3,878  $ 8,680  $ 5,116  $ 3,947  $ 9,064  $ 4,770  $ 3,846  $ 8,616  Life Sciences Integrated Diagnostic Solutions Preanalytical Systems $ 769  $ 718  $ 1,487  $ 774  $ 784  $ 1,558  $ 761  $ 792  $ 1,553  Diagnostic Systems 1,103  941  2,045  672  875  1,547  678  858  1,536  Total Integrated Diagnostic Solutions 1,872  1,659  3,532  1,446  1,659  3,106  1,438  1,651  3,089  Biosciences 465  678  1,143  485  709  1,194  475  766  1,241  Total segment revenues $ 2,337  $ 2,337  $ 4,675  $ 1,931  $ 2,368  $ 4,300  $ 1,914  $ 2,416  $ 4,330  Interventional Surgery (b) $ 891  $ 230  $ 1,121  $ 977  $ 264  $ 1,242  $ 820  $ 202  $ 1,022  Peripheral Intervention (b) 871  640  1,511  917  657  1,574  728  511  1,239  Urology and Critical Care (b) 815  315  1,130  787  323  1,110  536  240  777  Total segment revenues $ 2,577  $ 1,186  $ 3,762  $ 2,682  $ 1,244  $ 3,926  $ 2,084  $ 953  $ 3,037  Total Company revenues $ 9,716  $ 7,401  $ 17,117  $ 9,730  $ 7,560  $ 17,290  $ 8,768  $ 7,215  $ 15,983 